Trials
MRD trials
The curated index is a sourced list of studies. Accruing is the live ClinicalTrials.gov set of studies that are recruiting or not yet recruiting. DYNAMIC-III is not in the curated index because it is registered in Australia and New Zealand, not with an NCT id.
Recruiting and not-yet-recruiting studies that use ctDNA, cfDNA, or MRD in eligibility, a treatment decision, or a primary or secondary endpoint, plus observational studies focused on that testing. 1123 studies from 2267 registry records. Hematologic trials that list MRD only as a secondary endpoint are listed separately. Last synced Nov 18, 2026, 2:04 PM EST.
International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)
Charite University, Berlin, Germany · 21 locations · Updated 2026-10-26
Chidamide Maintenance to Prevent Relapse After Allogeneic Hematopoietic Stem Cell Transplantation in Acute T-Lymphoblastic Leukemia/Lymphoma
First Affiliated Hospital of Zhejiang University · Locations not reported · Updated 2026-08-19
A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia
Mats Heyman · 137 locations · Updated 2026-08-12
Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol
Institute of Hematology & Blood Diseases Hospital, China · 27 locations · Updated 2026-07-23
A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)
Ascentage Pharma Group Inc. · 90 locations · Updated 2026-04-30
NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19)
Health Institutes of Turkey · 4 locations · Updated 2026-03-30
CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT
Peking University People's Hospital · 1 locations · Updated 2026-02-27
Newly-diagnosed Pediatric Ph-positive B-ALL Protocol
Institute of Hematology & Blood Diseases Hospital, China · 24 locations · Updated 2025-09-03
Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol
Institute of Hematology & Blood Diseases Hospital, China · 27 locations · Updated 2025-08-26
Newly-diagnosed Pediatric T-cell ALL Protocol
Institute of Hematology & Blood Diseases Hospital, China · 27 locations · Updated 2025-08-26
Efficacy Study of Blinatumomab Clean Up Early Residual Disease for Newly Diagnosed Pediatric B Lymphoblastic Leukemia
Shanghai Jiao Tong University School of Medicine · 4 locations · Updated 2024-09-23
Combined Immuno-chemotherapy for Patients With B-linear Acute Lymphoblastic Leukemia Diagnosed From 0 to 365 Days of Life (ALL-Baby-2021)
Federal Research Institute of Pediatric Hematology, Oncology and Immunology · 1 locations · Updated 2024-06-28
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
National Cancer Institute (NCI) · 117 locations · Updated 2026-11-18
BEBT-908 Plus Chemotherapy Treatment for CR MRD-Positive MEF2D-Rearranged and Pre-B Acute Lymphoblastic Leukemia Patients
Ruijin Hospital · 1 locations · Updated 2026-11-17
Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL
Eastern Cooperative Oncology Group · 1 locations · Updated 2026-11-16
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
National Cancer Institute (NCI) · 229 locations · Updated 2026-11-12
Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for MRD-Positive B-ALL Patients in CR1
Ruijin Hospital · 1 locations · Updated 2026-11-12
TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II
Tanja Andrea Gruber · 24 locations · Updated 2026-11-12
A Study of Inotuzumab and Blinatumomab in People With B-cell Acute Lymphoblastic Leukemia
Memorial Sloan Kettering Cancer Center · 1 locations · Updated 2026-11-09
Inotuzumab as Post-Trasplantation Therapy for Adult High-risk B-cell Precursor Acute Lymphoblastic Leukemia
PETHEMA Foundation · 10 locations · Updated 2026-11-04
Intrathecal Chemoprophylaxis to Prevent Neurotoxicity Associated With Blinatumomab Therapy for Acute Lymphoblastic Leukemia
Northside Hospital, Inc. · 1 locations · Updated 2026-10-14
Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More Treatment
SWOG Cancer Research Network · Locations not reported · Updated 2026-10-13
A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)
Allotera Therapeutics · 18 locations · Updated 2026-09-28
Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)
H. Lee Moffitt Cancer Center and Research Institute · 1 locations · Updated 2026-09-25
UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL
University of Colorado, Denver · 1 locations · Updated 2026-09-14
Isatuximab in Adult Patients With Cytologic or Molecular Relapsed/Refractory CD38 Positive T-cell Acute Lymphoblastic Leukemia
Goethe University · 15 locations · Updated 2026-08-28
A Study of Obecabtagene Autoleucel in People With B-cell Acute Lymphoblastic Leukemia
Memorial Sloan Kettering Cancer Center · 9 locations · Updated 2026-08-20
A Study of CTD402 in T-ALL/LBL Patients
Imviva Bio · 9 locations · Updated 2026-08-19
Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
Etan Orgel · 16 locations · Updated 2026-08-19
Subcutaneous Blinatumomab Plus Ponatinib for BCR-ABL+ B-ALL
University of Alberta · 1 locations · Updated 2026-08-12
Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
St. Jude Children's Research Hospital · 4 locations · Updated 2026-08-10
Evaluation of Treatment Efficacy According to Risk Group in Relapsed Childhood Acute Lymphoblastic Leukemia
Ho Joon Im · 10 locations · Updated 2026-07-29
Treatment of Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia in Children
Hee Young Ju · 13 locations · Updated 2026-07-29
Treatment of Pediatric Very High-risk Acute Lymphoblastic Leukemia in Korea
Hyoung Jin Kang · 10 locations · Updated 2026-07-29
Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma
St. Jude Children's Research Hospital · 3 locations · Updated 2026-07-16
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Masonic Cancer Center, University of Minnesota · 1 locations · Updated 2026-06-25
Immuno-Targeted Therapy Plus Low-Dose Chemotherapy for Newly Diagnosed Adult Ph-Negative B-ALL: A Prospective Umbrella Trial
Institute of Hematology & Blood Diseases Hospital, China · Locations not reported · Updated 2026-06-11
Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)
Stephan Grupp MD PhD · 1 locations · Updated 2026-05-26
Cord Blood Transplantation in Children and Young Adults With Blood Cancer
Memorial Sloan Kettering Cancer Center · 1 locations · Updated 2026-05-14
TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL
Chinese PLA General Hospital · 6 locations · Updated 2026-05-08
Showing 1–40 of 101. Older studies
More hematologic trials (86) that list MRD only as a secondary endpoint
A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)
Merck Sharp & Dohme LLC · 30 locations · Updated 2026-11-10
Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia
Princess Maxima Center for Pediatric Oncology · 124 locations · Updated 2026-10-19
A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Lymphoblastic Leukaemia
Amgen · Locations not reported · Updated 2026-09-15
A Study of Injectable BLB101 and Blincyto® in Adult Participants With R/R CD19+ B-ALL
Institute of Hematology & Blood Diseases Hospital, China · Locations not reported · Updated 2026-07-23
A 3-cohort Randomized Study Evaluating the Role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Frontline Therapy of Adults With Acute Lymphoblastic Leukemia
Assistance Publique - Hôpitaux de Paris · 1 locations · Updated 2026-02-10
Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017
Martin Schrappe · 115 locations · Updated 2025-04-06
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
National Cancer Institute (NCI) · 285 locations · Updated 2026-11-18
Inotuzumab Plus Venetoclax in Older or Unfit Patients With Newly Diagnosed BCR::ABL1-Negative B-ALL
Ruijin Hospital · Locations not reported · Updated 2026-11-17
An All-Oral Combination of Ivosidenib, Sonrotoclax, and Chidamide for Newly Diagnosed Acute Myeloid Leukemia With an IDH1 Mutation (ISC)
First Affiliated Hospital of Zhejiang University · Locations not reported · Updated 2026-11-13
Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia
AstraZeneca · 27 locations · Updated 2026-11-13
Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)
Novartis Pharmaceuticals · 9 locations · Updated 2026-11-12
Palbociclib, All-Trans Retinoic Acid, and Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia
Second Affiliated Hospital of Nanchang University · 1 locations · Updated 2026-11-09
A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)
MSD R&D (China) Co., Ltd. · 11 locations · Updated 2026-10-30
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
National Cancer Institute (NCI) · 161 locations · Updated 2026-10-27
CD19 CAR-T Cell Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: A Phase I/II Study
Hospital Universitario Dr. Jose E. Gonzalez · 1 locations · Updated 2026-10-22
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)
Fred Hutchinson Cancer Center · 3 locations · Updated 2026-10-20
Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
City of Hope Medical Center · 8 locations · Updated 2026-10-13
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
AstraZeneca · 83 locations · Updated 2026-10-13
Immunotargeted Therapy Plus Low-Dose Chemotherapy in Newly Diagnosed Adult Ph+ B-ALL
Institute of Hematology & Blood Diseases Hospital, China · 1 locations · Updated 2026-09-25
A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents
Chongqing Precision Biotech Co., Ltd · 16 locations · Updated 2026-09-15
Zanubrutinib and Sonrotoclax for the Treatment of Relapsed Chronic Lymphocytic Leukemia /Small Lymphocytic Leukemia, ZeuS-2 Trial
City of Hope Medical Center · 3 locations · Updated 2026-09-10
ALL Backbone in AYAs
Dana-Farber Cancer Institute · 1 locations · Updated 2026-08-17
Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center · 1 locations · Updated 2026-05-20
Full-course Immunotherapy Combined With Chemotherapy in Newly Diagnosed B-cell Acute Lymphoblastic Leukemia
The First Affiliated Hospital of Soochow University · 1 locations · Updated 2026-05-04
Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
Beijing Biotech · 1 locations · Updated 2026-04-13
Co-administration of CART22-65s and huCART19 for B-ALL
Stephan Grupp MD PhD · 1 locations · Updated 2026-03-27
International Study for Treatment of High Risk Childhood Relapsed ALL 2010
Charite University, Berlin, Germany · 15 locations · Updated 2026-03-17
Safety and Efficacy of GYA01 (CART84) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic T Leukemia Patients (T-ALL).
Gyala Therapeutics · 2 locations · Updated 2026-03-13
Orphan Indications for CD19 Redirected Autologous T Cells
Stephan Grupp MD PhD · 1 locations · Updated 2026-03-06
SupCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies
Institute of Hematology & Blood Diseases Hospital, China · 1 locations · Updated 2025-12-15
Feasibility and Safety of Donor-derived NK-cell Infusions for Leukemia Relapse Prophylaxis After Hematopoietic Stem Cell Transplantation
Federal Research Institute of Pediatric Hematology, Oncology and Immunology · 1 locations · Updated 2025-12-01
Efficacy of Low-dose Venetoclax With Itraconazole + TACL for R/R ALL Patients
Hospital Universitario Dr. Jose E. Gonzalez · 1 locations · Updated 2025-10-02
A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)
Juventas Cell Therapy Ltd. · 9 locations · Updated 2025-08-12
Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia
Juventas Cell Therapy Ltd. · 11 locations · Updated 2025-08-08
Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for Newly Diagnosed B-cell ALL Patients in CR1
First Affiliated Hospital of Zhejiang University · Locations not reported · Updated 2025-01-15
CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL
Beijing Yongtai Ruike Biotechnology Company Ltd · 1 locations · Updated 2025-01-13
Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia
John Lister · 1 locations · Updated 2025-01-13
Venetoclax Combined With Olverembatinib and Predinisone in Treating Ph+ B-ALL
First Affiliated Hospital of Zhejiang University · 1 locations · Updated 2024-12-31
VHAG in Treating R/R T-ALL/LBL
First Affiliated Hospital of Zhejiang University · 1 locations · Updated 2024-12-19
Safety and Efficacy of CAR T Cell Therapy in Patients with R/r B-ALL
Kara Yakhteh Tajhiz Azma Company · 1 locations · Updated 2024-10-10
Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALL
First Affiliated Hospital of Zhejiang University · 1 locations · Updated 2024-08-15
Impact of Vitamin D on Gut Microbiome and Metabolome Among Pediatric Oncology Patients
Children's Hospital of Orange County · 1 locations · Updated 2026-11-16
A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
Autolus Limited · 15 locations · Updated 2026-11-13
CD19 Sequential CD22 In Vivo CAR-T Cell Immunotherapy for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
Liping Dou · 1 locations · Updated 2026-11-10
Busulfan-Based Versus TBI-Based Conditioning for Adult ALL-CR2 Allo-HSCT
Peking University People's Hospital · 1 locations · Updated 2026-11-05
Asciminib as Maintenance Treatment After Cellular Therapies for Adults With Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
City of Hope Medical Center · 1 locations · Updated 2026-11-03
Asciminib-Based Induction Therapy for the Treatment of Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
City of Hope Medical Center · 1 locations · Updated 2026-11-03
A Study of LP-118 In Combination With Ponatinib, Dexamethasone And Blinatumomab For Adults With Newly-Diagnosed, BCR::ABL1-Positive Acute Lymphoblastic Leukemia (ALL)
Wake Forest University Health Sciences · 2 locations · Updated 2026-10-29
Revumenib for the Treatment of Acute Leukemia in Patients Post-Allogeneic Stem Cell Transplant
City of Hope Medical Center · 1 locations · Updated 2026-10-19
Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia
City of Hope Medical Center · 1 locations · Updated 2026-10-16
CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies
British Columbia Cancer Agency · 7 locations · Updated 2026-10-14
Dual-Targeted Umbilical Cord Blood CAR-T Cells Against CD19 and CD22 for the Treatment of Relapsed or Refractory Acute B-Cell Lymphoblastic Leukemia
Ruijin Hospital · 1 locations · Updated 2026-09-25
SNC116 Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
Shanghai Simnova Biotechnology Co.,Ltd. · 1 locations · Updated 2026-09-21
U69-CART-Cells For R/R T-ALL
The First Affiliated Hospital of Soochow University · 1 locations · Updated 2026-09-02
First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Focused on Safety and How the Drug Behaves in the Body and Early Signs of Effect.
Allterum Therapeutics, Inc · 7 locations · Updated 2026-09-01
Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALL
Institute of Hematology & Blood Diseases Hospital, China · 4 locations · Updated 2026-08-26
MB-CART19.1 in Relapsed/Refractory Acute Lymphoblastic Leukemia
King Hussein Cancer Center · 1 locations · Updated 2026-08-05
Long-term Follow up Local Registry Study of Kymriah in South Korea
Novartis Pharmaceuticals · 18 locations · Updated 2026-07-30
Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL
Institute of Hematology & Blood Diseases Hospital, China · 1 locations · Updated 2026-07-23
Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia
University of Chicago · 2 locations · Updated 2026-06-29
Non-Interventional Study of Puzol-cel for CD19-Positive Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
Chongqing Precision Biotech Co., Ltd · Locations not reported · Updated 2026-06-10
Evaluation of the Safety and Efficacy of Sup19 CAR-T Cells in Patients With Previously Failed CD19-Targeted Therapy or CD19-Weakly Expressed Hematologic Tumors
Institute of Hematology & Blood Diseases Hospital, China · 1 locations · Updated 2026-04-20
A Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Kinetics of Universal Car-t Cell Injection in CD19 and / or CD20 Positive Relapsed / Refractory B-cell Acute Lymphoblastic Leukemia in Adolescents, Children and Adults
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · 1 locations · Updated 2026-03-13
Clinical Study on the Safety and Efficacy of BiTE-EV in Relapsed/Refractory Acute B-Cell Leukemia
Beijing GoBroad Hospital · 1 locations · Updated 2026-03-10
CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)
H. Lee Moffitt Cancer Center and Research Institute · 1 locations · Updated 2026-03-06
Clinical Trial of CMD63 Chimeric Antigen Receptor T-cell (CAR T-cell) in Children With Acute Lymphoblastic Leukemia (ALL)
Chulalongkorn University · 3 locations · Updated 2026-03-02
Efficacy and Safety of Chemotherapy Combined With CAR-T Cells in Newly Diagnosed Adult Patients With Ph- B-ALL
Institute of Hematology & Blood Diseases Hospital, China · 1 locations · Updated 2026-03-02
Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL
Institute of Hematology & Blood Diseases Hospital, China · 1 locations · Updated 2026-03-02
Treatment for Ph-negative ALL for Adults up to 65 Years
PETHEMA Foundation · 95 locations · Updated 2026-03-02
CIK Cell Therapy for Relapsed or Refractory Acute B-Lymphoblastic Leukemia: Prognostic Impact on Patients With Early CAR-T Cell Dysfunction
Beijing GoBroad Hospital · 1 locations · Updated 2026-02-25
Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia
Zhejiang University · 1 locations · Updated 2026-02-24
Immune-targeted Combination With Chemotherapy for Acute Leukemia of Ambiguous Lineage
Institute of Hematology & Blood Diseases Hospital, China · Locations not reported · Updated 2026-02-11
CD19 Chimeric Antigen Receptor (CAR) T Cells in Adults With Relapsed/Refractory CD19 Positive Acute Lymphoblastic Leukemia
King Faisal Specialist Hospital & Research Center · 1 locations · Updated 2026-01-22
Autologous Bedside CD19 CAR T-cell Therapy for B-ALL
The General Hospital of Western Theater Command · 1 locations · Updated 2025-12-11
Efficacy of Dose-Adjusted Regimen on Survival in Frail Adults With Acute Lymphoblastic Leukemia
Hospital General de Mexico · 1 locations · Updated 2025-12-02
Allogeneic UCB-derived CAR-T for B-ALL
The General Hospital of Western Theater Command · 1 locations · Updated 2025-12-01
CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL
University of Colorado, Denver · 1 locations · Updated 2025-11-28
A Clinical Study to Explore CT1195E in Patients With Relapsed/Refractory B-Cell Neoplasms
Institute of Hematology & Blood Diseases Hospital, China · 1 locations · Updated 2025-11-18
ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML
Marlise Luskin, MD · 4 locations · Updated 2025-11-04
Study of Nutrition and Exercise in Adults Hospitalized for Treatment of Acute Lymphoblastic Leukemia (ALL)
University of Chicago · 1 locations · Updated 2025-06-19
The Safety and Efficacy of VGO-Cs01p in Patients With CD7-positive Relapsed/Refractory Acute T-lymphoblastic Leukemia
Shanghai Jiao Tong University School of Medicine · Locations not reported · Updated 2025-05-15
CD-19 CAR-T Cell for Pediatric ALL or Lymphoma
Hong Kong Children's Hospital · 1 locations · Updated 2025-03-10
The Patient Cohort of the National Center for Precision Medicine in Leukemia
Assistance Publique - Hôpitaux de Paris · 3 locations · Updated 2024-05-29
Treatment of Breakpoint Cluster Region-Abelson (BCR-ABL) Negative ALL in Adults
PETHEMA Foundation · 108 locations · Updated 2022-02-18
A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy
He Huang · 1 locations · Updated 2020-12-28
A Study of GC019F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL
Peking University Third Hospital · Locations not reported · Updated 2020-10-20
Status can change after this sync. The curated list is the other view on this page. Evidence holds the published results.